Skip to main content
OpenTrials

Clinical trial condition

Smoldering Multiple Myeloma

Explore clinical trials studying Smoldering Multiple Myeloma. Study availability and eligibility vary by location and protocol.

44 public trials 15 recruiting studies
Refine in advanced search Browse all conditions

Smoldering Multiple Myeloma trial results

Active, not recruiting

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

NCT01169337

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Anchorage Oncology Centre Anchorage, Alaska, United States
  • Katmai Oncology Group Anchorage, Alaska, United States
View all 605 locations
View Trial Details
Active, not recruiting

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

NCT03236428

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Pacific Cancer Care Monterey, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
View Trial Details
Active, not recruiting

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

NCT02886065

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Weill Cornell Medical College New York, United States
View Trial Details
Active, not recruiting

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

NCT04850846

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Brigham and Women's Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Dana-Farber at Brighton Brighton, Massachusetts, United States
  • Dana-Farber at Merrimack Valley Methuen, Massachusetts, United States
View Trial Details
Active, not recruiting

Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.

NCT04144387

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • Cliniques Universitaires Saint-Luc Brussels, Belgium
  • Institut Jules Bordet Brussels, Belgium
  • CHU UCL Namur ASBL Site Godinne Yvoir, Belgium
  • Centre Hospitalier Abbeville, France
View all 90 locations
View Trial Details
Active, not recruiting

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

NCT03289299

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Moffitt Cancer Center Tampa, Florida, United States
  • University of Chicago Medical Center Chicago, Illinois, United States
  • Indiana University Simon Cancer Center Indianapolis, Indiana, United States
  • University of Kansas Cancer Center Westwood, Kansas, United States
View Trial Details
Active, not recruiting

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

NCT02415413

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • Hospital Clínic de Barcelona Barcelona, Spain
  • Hospital Universitari Germans Trias i Pujol Barcelona, Spain
  • Hospital Clínico San Carlos Madrid, Spain
  • Hospital Universitario 12 de Octubre Madrid, Spain
View all 16 locations
View Trial Details
Completed

A Real-world Study in Participants With Smoldering Multiple Myeloma

NCT06472778

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • CHRU de Tours - Hopital Trousseau Chambray-lès-Tours, France
  • CHU Montpellier Montpellier, France
  • Centre Hospitalier Regional d'Orleans (CHRO) - Hopital La Source Orléans, France
  • Hopital Pitie Salpetriere Paris, France
View all 29 locations
View Trial Details

Related conditions